We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Publishes MAPPs Update on Bioequivalence Studies With Clinical Endpoints
FDA Publishes MAPPs Update on Bioequivalence Studies With Clinical Endpoints
To reflect the more current organizational structure and processes in its Office of Generic Drugs (OGD), the FDA has published a manual of policies and procedures (MAPPs) update focused on bioequivalence (BE) studies with clinical endpoints.